Annual Meeting 2015: Combined Nivolumab and Ipilimumab or Monotherapy Shown Promise in Untreated Melanoma - 101271

Spotlight
Video

Annual Meeting 2015: Combined Nivolumab and Ipilimumab or Monotherapy Shown Promise in Untreated Melanoma

EMJ has 458 videos Subscribe Here

Loading........
Description: The randomised, double-blind, phase 3 CheckMate 067 trial showed that nivolumab alone or nivolumab plus ipilimumab significantly improved progression-free survival (PFS) in patients with metastatic melanoma compared with ipilimumab alone. The median PFS in the group treated with the combination therapy was 11.5 months compared with 6.9 months in the nivolumab monotherapy group and 2.9 months in the ipilimumab monotherapy group.

Presented by Jedd D. Wolchok, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, at ASCO 2015

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 06/04/15
Added : 3 years ago



Recommended

Nothing found.

More From EMJ

Nothing found.